

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 7/00, A61K 39/165</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/14083</b> <b>(43) International Publication Date:</b> 26 May 1995 (26.05.95)
<b>(21) International Application Number:</b> PCT/EP94/03801 <b>(22) International Filing Date:</b> 15 November 1994 (15.11.94) <b>(30) Priority Data:</b> 9323820.2 19 November 1993 (19.11.93) GB 9406480.5 31 March 1994 (31.03.94) GB  <b>(71) Applicant (for all designated States except US):</b> SMITHKLINE BEECHAM BIOLOGICALS (S.A.) [BE/BE]; 89, rue de l'Institut, B-1330 Rixensart (BE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HARFORD, Nigel, Maurice [NZ/BE]; 89, rue de l'Institut, B-1330 Rixensart (BE). COLAU, Brigitte, Desiree, Alberte [BE/BE]; SmithKline Beecham Biologicals (S.A.), 89, rue de l'Institut, B-1330 Rixensart (BE). DIDELEZ, Jean [BE/BE]; SmithKline Beecham Biologicals (S.A.), 89, rue de l'Institut, B-1330 Rixensart (BE).  <b>(74) Agent:</b> DALTON, Marcus, Jonathan, William; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BE (GB).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> VACCINE AGAINST MUMPS CONTAINING A JERYL-LYNN VIRUS STRAIN  <b>(57) Abstract</b>  A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and antibody titres than known commercial vaccines.		